This chapter aims to provide an outline of anti-EGFR drugs tested in advanced/metastatic BTCs, including GBCs along with the summary of various clinical trials done and the new ones proposed on anti-EGFR drugs in this disease setting.Bains, Lovenish...
Panitumumab (an anti-EGFR therapy) is part of certain 1L targeted treatment recommendations for left-sided mCRC from the National Comprehensive Cancer Network® (NCCN®) and ASCO.5,6 LEARN MORE ABOUT GUIDELINES The NCCN makes no warranties of any kind whatsoever regarding their content, use,...
While the approved use of drugs like the dual kinase inhibitor Lapatinib represents significant advances in the clinical management of breast cancer, confirmatory studies must be considered to foster the use of anti-EGFR therapies including safety, pharmacokinetics, and clinical efficacy. 展开 ...
The therapy and diagnostic is based on the findings that proliferation and tumor growth of specific EGFR bearing tumor tissue expressing an amplified EGFR gene copy number may be abolished by anti-EGFR antibodies, while other individual molecular alterations such as mutations occurring in tumor tissues...
Therapy monitoringPredictionAnti-EGFRAnti-VEGFMonoclonal antibody therapyIn developed countries, colorectal cancer (CRC) is the third most common malignancy, but... S Hagan,MCM Orr,B Doyle - 《Epma Journal》 被引量: 87发表: 2013年 Mechanisms of resistance to anti-EGFR monoclonal antibody treatment...
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532–6. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O,...
(DOR) of 17.5 months demonstrates sustained clinical benefits in responding patients, an ORR of 28% is still below our expectation for a targeted therapy. Meanwhile, the central nervous system (CNS) activity of currently approved drugs are unclear. The CHRYSALIS study and the pivotal study of ...
Cancer: Improving targeted therapy A new method for producing antibody-drug conjugates (ADCs), pairing anti-cancer drugs with antibodies that deliver them specifically to cancer cells, may help to develop therapies for hard-to-treat cancers. ADCs show promise for treating several cancers, but are ...
et al. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Int. J. Pharm. 592, 120082. https://doi.org/10.1016/j.ijpharm.2020.120082 (2021). Article CAS Google Scholar Gargari, S. L. M. & Adriani, R. R. In silico designing and ...
Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred and...